ALX Oncology Revenue and Competitors
Estimated Revenue & Valuation
- ALX Oncology's estimated annual revenue is currently $8.4M per year.
- ALX Oncology's estimated revenue per employee is $116,250
- ALX Oncology's total funding is $166M.
- ALX Oncology's current valuation is $749.2M. (January 2022)
Employee Data
- ALX Oncology has 72 Employees.
- ALX Oncology grew their employee count by 44% last year.
ALX Oncology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP, Clinical Development | Reveal Email/Phone |
3 | VP Clinical Operations and Clinical Outsourcing | Reveal Email/Phone |
4 | HEAD OF QA/QC | Reveal Email/Phone |
5 | VP, Operations | Reveal Email/Phone |
6 | VP, Chemistry, Manufacturing, and Controls | Reveal Email/Phone |
7 | VP Antibody Technologies | Reveal Email/Phone |
8 | VP, Research And Development | Reveal Email/Phone |
9 | VP, CMC | Reveal Email/Phone |
10 | VP, Finance & Chief Accounting Officer | Reveal Email/Phone |
ALX Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is ALX Oncology?
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
keywords:N/A
$166M
Total Funding
72
Number of Employees
$8.4M
Revenue (est)
44%
Employee Growth %
$749.2M
Valuation
N/A
Accelerator
ALX Oncology News
Get ALX Oncology alerts: Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. lifted its...
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that...
ALX Oncology Holdings (NASDAQ:ALXO) has filed for a $450M mixed shelf offering. The filing does not necessarily indicate that a sale has begun,...
The company plans to invest the money in its lead drug candidate, ALX148, a CD47-targeting checkpoint inhibitor that it is developing in combination with other therapies in solid tumors and blood cancers. The drug is designed to maximize the clinical benefit of other monoclonal antibodies. The ...
ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scientist for an ...
Other Companies in Burlingame
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.7M | 72 | -4% | N/A |
#2 | $14.3M | 72 | -1% | N/A |
#3 | $5.7M | 73 | 28% | $39.7M |
#4 | $4.8M | 73 | 9% | N/A |
#5 | $35M | 75 | -4% | N/A |